- ►diabetesjournals.org AV Matveyenko, S Dry, HI Cox, A Moshtaghian, … - Diabetes, 2009 - Am Diabetes Assoc OBJECTIVE We sought to establish the extent and mechanisms by which sitagliptin
and metformin singly and in combination modify islet disease progression in
human islet amyloid polypeptide transgenic (HIP) rats, a model for type 2 ... Cited by 2 - Related articles - All 2 versions
Y Moritoh, K Takeuchi, T Asakawa, O Kataoka … - British Journal of Pharmacology, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 3 - Related articles - All 2 versions
CF Deacon, JJ Holst - Advances in Therapy, 2009 - Springer Saxagliptin is a potent and selective reversi- ble inhibitor of dipeptidyl
peptidase-4, which is being developed for the treatment of type 2 diabetes. It
is absorbed rapidly after oral administration and has a pharmacokinetic ... Cited by 3 - Related articles - All 2 versions
A Woehl, M Evans, AP Tetlow, P McEwan - Cardiovascular Diabetology, 2008 - cardiab.com Exenatide belongs to a new therapeutic class in the treatment of diabetes
(incretin mimetics), allowing glucose-dependent glycaemic control in Type 2
diabetes. Randomised controlled trial data suggest that exenatide is as ... Cited by 4 - Related articles - Cached - All 9 versions
MA Bush, JE Matthews, EH De Boever, RL … - Diabetes Obes Metab, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 5 - Related articles - All 2 versions
[CITATION] on behalf of the Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 …
RE Pratley, MS Kipnes, PR Fleck, C Wilson, Q … - Diabetes Obes Metab, 2009 Cited by 6 - Related articles
[CITATION] Saxagliptin added to a sub-maximal dose sulfonylurea is safe and more efficacious than up- …
B Schwarz, M Gouveia, J Chen, G Nocea, K … - Diabetes, Obesity and Metabolism, 2008 - interscience.wiley.com Conflicts of interest: JC and JC are employees of Merck & Co., Inc. and hold
stock in the company. EA and DY are employees and share holders of Merck & Co.
KJ is an employee of Merck Sharp & Dohme Ltd. and holds shares in the ... Cited by 4 - Related articles - All 4 versions
[CITATION] for the LEAD 6 study group. Liraglutide once a day versus exenatide twice a day for type 2 …
